Huseyin Naci and colleagues examine the trade-off between the benefits of earlier access to cancer drugs through the FDA's accelerated approval pathway and the uncertainty surrounding their clinical efficacy at the time of market entry

Rose Higgins and colleagues quantify changes in opioid prescribing over time to a population with high rates of opioid use to understand the impact of longer elective wait times during the covid-19 pandemic